APA (7th ed.) Citation

Craig, T. J., Zaragoza-Urdaz, R. H., Li, H. H., Yu, M., Ren, H., Juethner, S., & Anderson, J. (2022). Effectiveness and safety of lanadelumab in ethnic and racial minority subgroups of patients with hereditary angioedema: Results from phase 3 studies. Allergy, Asthma & Clinical Immunology, 18(1), 1. https://doi.org/10.1186/s13223-022-00721-y

Chicago Style (17th ed.) Citation

Craig, Timothy J., Rafael H. Zaragoza-Urdaz, H. Henry Li, Ming Yu, Hong Ren, Salomé Juethner, and John Anderson. "Effectiveness and Safety of Lanadelumab in Ethnic and Racial Minority Subgroups of Patients with Hereditary Angioedema: Results from Phase 3 Studies." Allergy, Asthma & Clinical Immunology 18, no. 1 (2022): 1. https://doi.org/10.1186/s13223-022-00721-y.

MLA (9th ed.) Citation

Craig, Timothy J., et al. "Effectiveness and Safety of Lanadelumab in Ethnic and Racial Minority Subgroups of Patients with Hereditary Angioedema: Results from Phase 3 Studies." Allergy, Asthma & Clinical Immunology, vol. 18, no. 1, 2022, p. 1, https://doi.org/10.1186/s13223-022-00721-y.